Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Avenida la Plaza 680, Las Condes, Santiago 7610658, Chile.
Int J Mol Sci. 2022 Feb 28;23(5):2669. doi: 10.3390/ijms23052669.
Drug-induced liver injury (DILI) is one of the leading causes of acute liver injury. Many factors may contribute to the susceptibility of patients to this condition, making DILI a global medical problem that has an impact on public health and the pharmaceutical industry. The use of mesenchymal stem cells (MSCs) has been at the forefront of regenerative medicine therapies for many years, including MSCs for the treatment of liver diseases. However, there is currently a huge gap between these experimental approaches and their application in clinical practice. In this concise review, we focus on the pathophysiology of DILI and highlight new experimental approaches conceived to improve cell-based therapy by the in vitro preconditioning of MSCs and/or the use of cell-free products as treatment for this liver condition. Finally, we discuss the advantages of new approaches, but also the current challenges that must be addressed in order to develop safer and more effective procedures that will allow cell-based therapies to reach clinical practice, enhancing the quality of life and prolonging the survival time of patients with DILI.
药物性肝损伤（DILI）是急性肝损伤的主要原因之一。许多因素可能导致患者易患这种疾病，使 DILI 成为一个影响公共健康和制药行业的全球性医疗问题。间充质干细胞（MSCs）的应用多年来一直处于再生医学治疗的前沿，包括用于治疗肝脏疾病的 MSCs。然而，这些实验方法与临床实践的应用之间存在巨大差距。在这篇简明的综述中，我们重点关注 DILI 的病理生理学，并强调了新的实验方法，这些方法设想通过体外预处理 MSC 和/或使用无细胞产物作为治疗这种肝脏疾病来改善基于细胞的治疗。最后，我们讨论了新方法的优势，但也讨论了当前必须解决的挑战，以便开发更安全、更有效的程序，使基于细胞的治疗能够进入临床实践，提高 DILI 患者的生活质量和延长其生存时间。
